The legal cannabis market is worth $10.4 billion, but it’s expected to grow to $75.6 billion by 2025.
That’s growth of 627%. And it means you should be looking for the best cannabis stocks in 2020. In fact, our best pot stock is poised for 218% growth.
The backdrop couldn’t be better for weed stocks. The rise of legalization has created a growing market. Already, 11 states have made recreational marijuana fully legal, and 33 states have made marijuana for medical purposes legal. The result is an industry worth $10.4 billion.
Meticulous Research expects the worldwide cannabis market to soar more than 28% every year, starting now and extending to 2025. That’s when the market is set to hit $75.6 billion.
And our top marijuana stock will get a big piece of that.
We found it using our proprietary Money Morning Stock VQScore™. It rates stocks on a scale from 1 to 4.9. The higher the rating, the better the stock is likely to be for investors.
Now, many weed stocks don’t even make it to the VQScore list. That’s because they’re still unprofitable, fledgling companies. The VQScore looks at profit potential.
But now we’re seeing a top pot stock with a perfect 4.9 VQScore. It’s the first marijuana stock to be rated this highly – the strongest possible buy.
And that’s because this marijuana stock has 218% growth potential.
The Best Weed Stock in 2020
Canada’s Cronos Group Inc. (NASDAQ: CRON) shares have lost roughly half their value since the winter of 2018. But there’s a silver lining in that glum performance. Given its worth, the current share price, $7.86, is a bargain.
Right now, the U.S. Centers for Disease Control and Prevention is investigating links between vaping and acute lung illnesses.
An increasing number of cases have been reported over the last few weeks. It has no doubt hurt CRON and other cannabis companies.
But the fall of publicly traded marijuana stocks is an overreaction. CRON’s products are unrelated to the vaping incidents – rather, many have been traced back to homemade, black market products used in places where marijuana is still illegal.
In fact, many hospitalized patients indicate they have purchased illegal e-liquids containing THC from vendors without a license. But the public’s view of the disease has tarnished smoke and vaping products for the time being.
Now, CRON can’t control perceptions, but investors know that the stock is currently a bargain. It’s soon to make a huge rally.
Cronos Is Making Money
Cronos has a strong strategic plan. This spring, it signed a cash deal with cigarette maker Altria Group Inc. (NYSE: MO). MO obtained 45% of CRON in exchange for $1.8 billion.
With the money, Cronos management is in a position to strategically acquire and grow its market share vis-à-vis competitors.
Plus, MO is a terrific strategic partner for a company like Cronos, with major marketing heft and streamlined brand expansion possibilities.
CRON also has a clear identity. It intends to be a major cannabidiol (CBD) company. It focuses on higher-margin entries that can be produced by its growing network.
In 2018, CRON lost $14.6 million. It’s now in a major profit turnaround. In the first two quarters of 2019, the company made profits of $323 million and $187 million.
Last quarter, revenue rose by 120% year over year. Wall Street analysts forecast revenue of more than $60 million in 2019 – 283% annual growth.
Expectations place the target price for CRON at $25 by year-end 2020. That’s a skyrocketing 184% profit potential.
Source: Money Morning